Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 10/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918766 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TSHRMAPK1CASP3CCR1 | |
| SCHEMBL23918399 | 0.87 | SMN1; SMN2 (0.41) | ALDH1A1TSHRMAPK1CASP3KMT2A | |
| SCHEMBL24379693 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHRMAPK1CASP3CCR1 | |
| SCHEMBL23918394 | 0.84 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPK1CASP3CCR1 | |
| SCHEMBL29428234 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPK1CASP3CCR1 | |
| SCHEMBL23918753 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPK1CASP3CCR1 | |
| SCHEMBL24379691 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPK1CASP3CCR1 | |
| SCHEMBL27792865 | 0.79 | CASP3 (0.65) | ALDH1A1TSHRMAPK1CASP3KMT2A | |
| SCHEMBL24379692 | 0.77 | ADORA1 (0.40) | ALDH1A1TSHRKMT2AAKR1C3AKR1C2 | |
| SCHEMBL23910261 | 0.76 | KDM4E (0.44) | ALDH1A1CASP3KMT2ALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3700907-B1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | ALDH1A1 1120/4885TSHR 2897/4885MAPK1 2087/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | ALDH1A1 1149/4885TSHR 3113/4885MAPK1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.